Maastricht University Medical Center
Maastricht, Zuid-Limburg, 6202AZ, Netherlands
NCT Number: NCT03227835
After administration of intravascular iodinated contrast media Contrast-Induced Nephropathy (CIN), also known as Contrast-Induced Acute Kidney Injury (CIAKI), may occur. CIN/CI-AKI is associated with increased risk of dialysis and mortality. No treatment exists for CIN/CI-AKI, therefore the focus lies on prevention. Clinical practice guidelines for the prevention of CIN/CI-AKI exist and are implemented in most hospitals. Generally, intravascular volume expansion with normal saline is recommended as prophylaxis.
Earlier this year the results of the AMACING study (A MAastricht Contrast-Induced Nephropathy Guideline study) were published in The Lancet (NL47173.068.14/METC 14-2-006; Clinical Trials.gov NCT02106234; http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30057-0/fulltext). These results show that for the greater part (>90%) of patients considered to be at risk of CIN/CI-AKI by the guidelines, withholding prophylaxis is non-inferior to giving standard intravenous prophylactic hydration in the prevention of CIN/CI-AKI. Furthermore, the standard prophylactic hydration confers some risk (5.5% complications of intravenous hydration were recorded in the AMACING study).
As a result the clinical protocol in the Maastricht University Medical Centre (MUMC+) has been adapted, and patients with an estimated Glomerular Filtration Rate (eGFR) >29mL/min/1.73m2 no longer receive intravenous prophylactic hydration before or after procedures with intravascular iodinated contrast material administration.
CINART is a one year prospective observational study with the aim to evaluate the consequences of the protocol change for 1. for incidences of CIN/CI-AKI, dialysis and mortality, 2. for clinical practice in terms of patient burden (complications of prophylaxis), hospital burden (extra hospitalisations for prophylaxis), and costs, as derived from the number of elective procedures carried out in patients formerly eligible for prophylaxis.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Maastricht, Zuid-Limburg, 6202AZ, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR >29mL/min/1.73m2
Time frame: 1 year
Number of elective procedures with intravascular contrast in patients formerly eligible for prophylaxis
Time frame: 2-6 days post contrast administration
>25% or >44umol/L increase in serum creatinine from baseline
Time frame: 26-35 days post-contrast
incidences of dialysis
Time frame: 26-35 days post-contrast
incidences of all-cause mortality
Maastricht University Medical Center
Other
Acronym: CINART
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04864847
Acute Kidney Injury, Contrast-induced Nephropathy
Chandler, Arizona, United States
View Trial DetailsNCT07184918
Acute Kidney Injury, Contrast-induced Nephropathy
Tanta, Gharbia Governorate, Egypt
View Trial DetailsNCT07022626
Arterial Occlusive Diseases, Arteriosclerosis
London, United Kingdom
View Trial DetailsNCT04163484
Acute Kidney Injury, Angina Pectoris
Moscow, Russia
View Trial Details